EMA Finalizes Pharmacovigilance Guidelines

Article

The European Medicines Agency has published its first set of finalized guidelines concerning good pharmacovigilance practices.

The European Medicines Agency (EMA) has published its first set of finalized guidelines concerning good pharmacovigilance practices (GVP). The guidelines are a key deliverable of Europe’s pharmacovigilance legislation, which will come into effect on July 2, 2012.

Several modules make up the GVP package. Seven modules have been finalized so far concerning pharmacovigilance systems and their quality systems, pharmacovigilance systems’ master files, risk-management systems, management and reporting of adverse drug reactions to medicinal products, periodic safety update reports, postauthorization safety studies, and signal management.

Each module was released for consultation between February and April 2012 and the final versions reflect some of the comments received. Each module was developed by a team of experts from the EMA and EU member states.

More modules are also under development, including modules for pharmacovigilance inspections and additional monitoring, and will be released for consultation later in the year.

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content